Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 16, 2020
Daily News
June 16, 2020
- Japan Stiffens Foreign Investment Rules for Certain Drug, Medical Device Manufacturers
June 16, 2020
- Oncolys Inks US$300 Million-Plus Pact for OBP-601; Potential for Neurodegenerative Diseases Eyed
June 16, 2020
- Meiji/Solasia Plan Japan NDA for PTCL Med in First Half of 2021
June 16, 2020
- Taiho Files Aloxi for Pediatric Use
June 16, 2020
- Poteligeo Now Available in Germany: Kyowa Kirin
June 16, 2020
- MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue
June 16, 2020
- Mitsubishi Tanabe Launches PIII Dersimelagon Study for Rare Protoporphyria, Targeting US Filing in FY2021
June 16, 2020
- Kaken’s Axillary Hyperhidrosis Treatment Hits Primary Goal in Japan PIII Study
June 16, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…